Display options
Cite
Yılmaz N, Ağuş N, Bayram A, et al. Antimicrobial susceptibilities of Escherichia coli isolates as agents of community-acquired urinary tract infection (2008-2014). Turk J Urol. 2016;42(1):32-6doi: 10.5152/tud.2016.90836.
Yılmaz, N., Ağuş, N., Bayram, A., Şamlıoğlu, P., Şirin, M. C., Derici, Y. K., & Hancı, S. Y. (2016). Antimicrobial susceptibilities of Escherichia coli isolates as agents of community-acquired urinary tract infection (2008-2014). Turkish journal of urology, 42(1), 32-6. https://doi.org/10.5152/tud.2016.90836
Yılmaz, Nisel, et al. "Antimicrobial susceptibilities of Escherichia coli isolates as agents of community-acquired urinary tract infection (2008-2014)." Turkish journal of urology vol. 42,1 (2016): 32-6. doi: https://doi.org/10.5152/tud.2016.90836
Yılmaz N, Ağuş N, Bayram A, Şamlıoğlu P, Şirin MC, Derici YK, Hancı SY. Antimicrobial susceptibilities of Escherichia coli isolates as agents of community-acquired urinary tract infection (2008-2014). Turk J Urol. 2016 Mar;42(1):32-6. doi: 10.5152/tud.2016.90836. PMID: 27011879; PMCID: PMC4791079.
Copy Download .nbib Format: NLM
Share it on

Turk J Urol. 2016 Mar;42(1):32-6. doi: 10.5152/tud.2016.90836.

Antimicrobial susceptibilities of Escherichia coli isolates as agents of community-acquired urinary tract infection (2008-2014).

Turkish journal of urology

Nisel Yılmaz, Neval Ağuş, Arzu Bayram, Pınar Şamlıoğlu, M Cem Şirin, Yeşer Karaca Derici, Sevgi Yılmaz Hancı

Affiliations

  1. Clinic of Microbiology, ?zmir Tepecik Training and Research Hospital, ?zmir, Turkey.

PMID: 27011879 PMCID: PMC4791079 DOI: 10.5152/tud.2016.90836

Abstract

OBJECTIVE: Urinary tract infections (UTIs) are among the most frequently seen community-acquired infections worldwide. E. coli causes 90% of urinary system infections. To guide the empirical therapy, the resistance pattern of E. coli responsible for community-acquired UTI was evaluated throughout a seven-year period in this study.

MATERIAL AND METHODS: The urine cultures of patients with urinary tract infections admitted to outpatient clinics between 1(st) January 2008 and 31(st) December 2014 were analyzed. Presence of ≥10(5) colony-forming units/mL in urine culture media was considered as significant for UTI. Isolated bacteria were identified by standard laboratory techniques or automated system VITEK2 (BioMerieux, France) and BD PhoenixTM 100 (BD, USA), as required. Antibiotic susceptibility testing was performed by Kirby-Bauer disk diffusion method using Clinical Laboratory Standard Institute (CLSI) criteria.

RESULTS: A total of 13281 uropathogens were isolated. Overall E. coli accounted for 8975 (67%) of all isolates. Resistance rates of E. coli to antimicrobial agents was demonstrated to be as follows: ampicillin 66.9%, cefazolin 30.9%, cefuroxime 30.9%, ceftazidime 14.9%, cefotaxime 28%, cefepime 12%, amoxicillin-clavulanic acid 36.9%, trimethoprim-sulfamethoxazole (TMP-SXT) 20%, ciprofloxacin 49.9%, amikacin 0.3%, gentamycin 24%, nitrofurantoin 0.9%, and fosfomycin 4.3%. There was no resistance to imipenem nor meropenem. The frequency of ESBL-producing E. coli strains was 24%.

CONCLUSION: It is concluded that fosfomycin and nitrofurantoin are appropriate empirical therapy for community-acquired UTI empirical therapy, but the fluoroquinolones and the TMP-SXT shall not be used in the emprical treatment of UTI at this stage. In conclusion, as resistance rates show regional differences, it is necessary to regularly examine regional resistance rates to determine the appropriate empiric antibiotic treatment and national antibiotic usage policies must be reorganized according to data obtained from these studies.

Keywords: Antimicrobial susceptibility; Escherichia coli; community-acquired urinary tract infections

References

  1. Clin Infect Dis. 2011 Mar 1;52(5):e103-20 - PubMed
  2. Indian J Med Sci. 2012 Nov-Dec;66(11-12):273-9 - PubMed
  3. Int J Antimicrob Agents. 2012 Jan;39(1):45-51 - PubMed
  4. J Chemother. 2010 Oct;22(5):355-7 - PubMed
  5. Med Sci Monit. 2009 Nov;15(11):PI61-5 - PubMed
  6. J Clin Diagn Res. 2014 Sep;8(9):DC09-12 - PubMed
  7. Int J Antimicrob Agents. 2002 Dec;20(6):407-11 - PubMed
  8. Int J Antimicrob Agents. 2007 Jan;29(1):62-5 - PubMed
  9. Mikrobiyol Bul. 2013 Oct;47(4):603-18 - PubMed
  10. BMC Infect Dis. 2012 Sep 18;12:222 - PubMed
  11. J Antimicrob Chemother. 2005 Nov;56(5):914-8 - PubMed
  12. J Formos Med Assoc. 2014 Dec;113(12):970-3 - PubMed
  13. Turk J Urol. 2013 Dec;39(4):237-43 - PubMed
  14. Int J Clin Pract. 2015 Jul;69(7):766-70 - PubMed
  15. Int J Antimicrob Agents. 2012 Dec;40(6):554-6 - PubMed
  16. J Infect Dev Ctries. 2010 May 01;4(4):202-6 - PubMed

Publication Types